Merial Selects Genostar's IOGMA Metabolic Pathway Builder Bioinformatics Software
News Apr 23, 2008
Genostar, a developer of bioinformatics software that enables biologists and bioinformaticians to mine and analyze diverse biological data, has announced that Merial has purchased its IOGMA® 3.4 Metabolic Pathway Builder software.
Genostar's IOGMA® 3.4 Metabolic Pathway Builder is a new package that integrates three modules of the company's successful bioinformatics products - GenoAnnot, ProteoAnnot, and PathwayExplorer. The package can offer a number of different tools used to analyze high throughput bacterial genome, protein, and metabolism (-omics) data.
Another key benefit of the package consists of Genostar's microB, a managed database of more than 450 microbial organisms, sourced and then standardized from many commonly used but very differently organized reference databases around the world. MicroB's coordinated data will help Merial access large amounts of cross-linked genome, protein, and metabolic data efficiently, the company says.
"With IOGMA 3.4 Metabolic Pathway Builder in our labs, our research teams now have access to improved tools and data that allow us to increase our productivity in our innovative research programs," said Dr. Jean-Christophe Audonnet, Senior Director, Discovery Research, Vaccinomics and Recombinant Vaccines at Merial. "This added expertise will maintain Merial's position as the leading company in veterinary vaccinology."
Designed to analyze various microorganism strains, IOGMA 3.4 enables biologists to investigate, for example, virulent, disease-causing pathogens. This type of research could potentially lead to strategies to prevent catastrophic diseases due to viruses, bacteria or parasites in domestic or wild animals.
"New discovery techniques through bioinformatics are being actively sought by vaccine developers," said Jean-François Mouret, Director of Business Development at Genostar. "By using our IOGMA 3.4 Metabolic Pathway Builder, pharmaceutical research teams will save on laboratory development costs, and bring results to their customers sooner."